ES2851602T3

3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors

Abstract

A compound selected from the group consisting of: 3- [4 - ({[(2-fluoro-5-methylphenyl) amino] carbonyl} amino) phenyl] -5 - ({[(3-methoxypropyl) amino] carbonyl} amino) isothiazole-4-carboxamide; Ethyl {4- (aminocarbonyl) -3- [4 - ({[(2-fluoro-5-methylphenyl) amino] carbonyl} amino) phenyl] isothiazol-5-yl} carbamate; 3- [4 - ({[(2-fluoro-5-methylphenyl) amino] carbonyl} amino) phenyl] -5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) isothiazole-4- carboxamide; 3- {4- [3- (2-Fluoro-5-methyl-phenyl) -ureido] -2-methyl-phenyl} -5- [3- (3-morpholin-4-yl-propyl) - acid amide ureido] -isothiazole-4-carboxylic; 3- [3- (4-carbamoyl-3- {4- [3- (2-fluoro-5-methyl-phenyl) -ureido] -phenyl} -isothiazol-5-yl) -ureido] -propionic acid; 3- [3- (4-carbamoyl-3- {4- [3- (2-fluoro-5-methyl-phenyl) -ureido] -2-methyl-phenyl} -isothiazol-5-yl) -ureido] acid -propionic; 3- [4 - ({[(3-methylphenyl) amino] carbonyl} amino) phenyl] -5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) isothiazole-4-carboxamide; 3- [2-methyl-4- (3-m-tolyl-ureido) -phenyl] -5- [3- (3-morpholin-4-yl-propyl) -ureido] -isothiazole-4-carboxylic acid amide ; 3- (3- {4-carbamoyl-3- [4- (3-m-tolyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 3- (3- {4-carbamoyl-3- [2-methyl-4- (3-m-tolyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 3- {4 - [({[2-fluoro-5- (trifluoromethyl) phenyl] amino} carbonyl) amino] phenyl} -5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) isothiazole -4-carboxamide; 3- {4- [3- (2-Fluoro-5-trifluoromethyl-phenyl) -ureido] -2-methyl-phenyl} -5- [3- (3-morpholin-4-yl-propyl) - acid amide ureido] -isothiazole-4-carboxylic; 3- [3- (4-carbamoyl-3- {4- [3- (2-fluoro-5-trifluoromethyl-phenyl) -ureido] -phenyl} -isothiazol-5-yl) -ureido] -propionic acid; 3- [3- (4-carbamoyl-3- {4- [3- (2-fluoro-5-trifluoromethyl-phenyl) -ureido] -2-methylphenyl} -isothiazol-5-yl) -ureido] -propionic acid ; 3- {4 - [(anilinocarbonyl) amino] phenyl} -5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) isothiazole-4-carboxamide; 3- [2-methyl-4- (3-phenyl-ureido) -phenyl] -5- [3- (3-morpholin-4-yl-propyl) -ureido] -isothiazole-4-carboxylic acid amide; 3- (3- {4-carbamoyl-3- [4- (3-phenyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 3- (3- {4-carbamoyl-3- [2-methyl-4- (3-phenyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] -5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) isothiazole-4-carboxamide; 3- [2-methyl-4- (3-p-tolyl-ureido) -phenyl] -5- [3- (3-morpholin-4-yl-propyl) -ureido] -isothiazole-4-carboxylic acid amide ; 3- (3- {4-carbamoyl-3- [2-methyl-4- (3-p-tolyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 3- (3- {4-carbamoyl-3- [4- (3-p-tolyl-ureido) -phenyl] -isothiazol-5-yl} -ureido) -propionic acid; 5 - ({[(3-morpholin-4-ylpropyl) amino] carbonyl} amino) -3- (4 - {[3- (trifluoromethyl) benzoyl] amino} phenyl) isothiazole-4-carboxamide; 3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] -5 - {[(2-oxopyrrolidin-1-yl) carbonyl] amino} isothiazole-4-carboxamide; 4 - {[({4- (aminocarbonyl) -3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] isothiazol-5-yl} amino) carbonyl] amino} butanoic acid; Methyl 4 - {[({4- (aminocarbonyl) -3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] isothiazol-5-yl} amino) carbonyl] amino} butanoate; 5 - ({[(3-hydroxypropyl) amino] carbonyl} amino) -3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] isothiazole-4-carboxamide; 5-amino-3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] isothiazole-4-carboxamide; 5-amino-3- [4 - ({[(2-fluoro-5-methylphenyl) amino] carbonyl} amino) phenyl] isothiazole-4-carboxamide; and 3- [4 - ({[(4-methylphenyl) amino] carbonyl} amino) phenyl] -5 - ({[(3-pyrrolidin-1-ylpropyl) amino] carbonyl} amino) isothiazole-4-carboxamide; or a pharmaceutically acceptable salt thereof.

Term

6.3 yearsto projected expiry

Projected expiry 27 December 2032, counted from filing; an application has no term until it is granted.

  1. Priority
  2. Filed
  3. Published
  4. Today
  5. Projected expiry

9 members in 4 offices

This recordMember, by publication datePriority claim

Priority claims5

Priority claims
DocumentOfficeKindDate
201161581031United States of AmericaP
201161581031United States of AmericaP
201161581031PUnited States of America
201161581031P
US201161581031P

Members9

Family members, oldest first
DocumentOfficeKind
US2013172353A1United States of AmericaA1
WO2013101954A1World Intellectual Property Organization (WIPO)A1
EP2797916A1European Patent Office (EPO)A1
US8969583B2United States of AmericaB2
EP2797916B1European Patent Office (EPO)B1
EP3184525A1European Patent Office (EPO)A1
ES2623652T3SpainT3
EP3184525B1European Patent Office (EPO)B1
ES2851602T3This recordSpainT3